Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Roflumilast in Chinese COPD Patients
NCT02671942Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Area under the plasma concentration versus drug dose at 8 weeks. Started Mar 2016; status: terminated.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02671942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671942.